>
Switch to:

Horizon Therapeutics Price-to-Owner-Earnings

: 96.54 (As of Today)
View and export this data going back to 2011. Start your Free Trial

As of today (2021-10-19), Horizon Therapeutics's share price is $112.95. Horizon Therapeutics's Owner Earnings per Share (TTM) ended in Jun. 2021 was $1.17. It's Price-to-Owner-Earnings for today is 96.54.


The historical rank and industry rank for Horizon Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

NAS:HZNP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.02   Med: 43.29   Max: 555.18
Current: 96.69

15.02
555.18

During the past 13 years, the highest Price-to-Owner-Earnings of Horizon Therapeutics was 555.18. The lowest was 15.02. And the median was 43.29.


NAS:HZNP's Price-to-Owner-Earnings is ranked lower than
99.99% of the 44 Companies
in the Drug Manufacturers industry.

( Industry Median: 17.71 vs. NAS:HZNP: 96.69 )

As of today (2021-10-19), Horizon Therapeutics's share price is $112.95. Horizon Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $2.25. Therefore, Horizon Therapeutics's PE Ratio for today is 50.20.

As of today (2021-10-19), Horizon Therapeutics's share price is $112.95. Horizon Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $2.25. Therefore, Horizon Therapeutics's PE Ratio without NRI for today is 50.20.

During the past 13 years, Horizon Therapeutics's highest PE Ratio without NRI was 208.89. The lowest was 8.84. And the median was 50.24.


Horizon Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Horizon Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.49 - 72.64 43.15 71.16

Horizon Therapeutics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 405.69 272.56 71.16 70.75 80.17

Competitive Comparison

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Horizon Therapeutics Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's Price-to-Owner-Earnings falls into.



Horizon Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Horizon Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=112.95/1.17
=96.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Horizon Therapeutics  (NAS:HZNP) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Horizon Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics Business Description

Horizon Therapeutics logo
Industry
Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, 1st Floor, Dublin, IRL, D04 C5Y6
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.
Executives
Sherman Jeffrey W officer: EVP and Chief Medical Officer C/O IDM PHARMA, INC. 9 PARKER, SUITE 100 IRVINE CA 92618
Camardo Daniel A. officer: EVP and President, U.S. C/O HORIZON THERAPEUTICS, PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 D04 C5Y6
Konstantinovsky Irina officer: EVP, Chief Human Resources Off C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4
Beeler Brian K officer: EVP, General Counsel C/O HORIZON PHARMA PLC 520 LAKE COOK ROAD, SUITE 520 DEERFIELD IL 60015
Hoelscher Paul W. officer: EVP, CFO 520 LAKE COOK ROAD, SUITE 520 C/O HORIZON PHARMA, INC. DEERFIELD IL 60062
Walbert Timothy P director, officer: Chairman, President and CEO 1033 SKOKIE BOULEVARD SUITE 355 NORTHBROOK IL 60062
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Santini Gino director C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Karnani Vikram officer: EVP & President, International C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE 1ST FLOOR, 1 BURLINGTON RD DUBLIN L2 4
Witz Pascale director C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO CA 92121
Shannon James Samuel director 28903 NORTH AVENUE PAINE VALENCIA CA 91355
Kent Jeff officer: See remarks C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4
Moze Barry officer: EVP, Chief Admin. Officer C/O HORIZON PHARMA, INC. 520 EAST COOK ROAD, SUITE 520 DEERFIELD IL 60015
Mchugh Miles W officer: Sr VP & Princ. Acctg Officer C/O ACCRETIVE HEALTH, INC. 401 N. MICHIGAN AVE, SUITE 2700 CHICAGO IL 60611
Curtis Geoffrey M. officer: EVP, Corporate Affairs, CCO C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 L2 4

Horizon Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)